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The Journal of Immunology
Myelin-Reactive, TGF-b–Induced Regulatory T Cells Can Be
Programmed To Develop Th1-Like Effector Function but
Remain Less Proinflammatory Than Myelin-Reactive Th1
Effectors and Can Suppress Pathogenic T Cell Clonal
Expansion In Vivo
Richard A. O’Connor,*,†,‡ Melanie D. Leech,*,†,‡ Janine Suffner,x Gu¨nter J. Ha¨mmerling,x
and Stephen M. Anderton*,†,‡
Interest in the use of regulatory T cells (Tregs) as cellular therapeutics has been tempered by reports of naturally occurring Tregs
losing Foxp3 expression and producing IL-17, raising concerns over a switch to pathogenic function under inflammatory conditions
in vivo. TGF-b–induced Tregs (inducible Tregs [iTregs]), generated in large numbers in response to disease-relevant Ags, repre-
sent the most amenable source of therapeutic Tregs. Using Foxp3-reporter T cells recognizing myelin basic protein (MBP), we
investigated the capacity of iTregs to produce effector-associated cytokines under proinflammatory cytokine conditions in vitro
and whether this translated into proinflammatory function in vivo. In contrast with naturally occurring Tregs, iTregs resisted
conversion to an IL-17–producing phenotype but were able to express T-bet and to produce IFN-g. iTregs initiated their T-bet
expression during their in vitro induction, and this was dependent on exposure to IFN-g. IL-12 reignited iTreg expression of T-bet
and further promoted iTreg production of IFN-g upon secondary stimulation. Despite losing Foxp3 expression and expressing
both T-bet and IFN-g, MBP-responsive IL-12–conditioned iTregs induced only mild CNS inflammation and only when given in
high numbers. Furthermore, iTregs retained an ability to suppress naive T cell clonal expansion in vivo and protected against the
development of experimental autoimmune encephalomyelitis. Therefore, despite bearing predictive hallmarks of pathogenic
effector function, previously Foxp3+ iTregs have much lower proinflammatory potential than that of MBP-responsive
Th1 cells. Our results demonstrate that autoprotective versus autoaggressive functions in iTregs are not simply a binary relation-
ship to be determined by their relative expression of Foxp3 versus T-bet and IFN-g. The Journal of Immunology, 2010, 185:
7235–7243.
M
osmann and Coffman’s (1) division of Th cells into the
Th1 and Th2 subsets gave a mechanistic basis (dif-
ferential cytokine production) for protective immune
responses against intracellular pathogens and extracellular para-
sites, respectively. Lineage-specific transcription factors (T-bet for
Th1 and GATA-3 for Th2) gave a molecular basis to this division.
The impetus toward further subdivision of effector function has
increased recently. Th17 cells express the transcription factors
retinoic acid receptor related orphan receptor (ROR)gT and RORa
(2, 3) and produce IL-17A, IL-17F, and IL-22 (reviewed in Ref.
4). Each of the above effector T cell “lineages” can have immu-
nopathological properties if directed against self or otherwise in-
nocuous non-self Ags (5–7). Counteracting these pathological
consequences of CD4+ Th cells, thymically derived naturally oc-
curring CD4+ regulatory T cells (nTregs) expressing the Foxp3
transcription factor limit the activation and expansion of autore-
active T cells, thereby providing dominant peripheral tolerance
(8). Continual expression of Foxp3 is required within regulatory
T cells (Tregs) for maintenance of their suppressive phenotype
(9–11).
With a view to the therapeutic application of Tregs, the char-
acterization of culture conditions (TGF-b plus IL-2 plus TCR
stimulation) that drive the de novo expression of Foxp3 in so-
called inducible Tregs (iTregs) was a major advance, providing the
opportunity to expand freshly produced Tregs from non-Treg
precursors (12). Proof of principle for Treg-mediated therapy
was provided by prevention and cure of autoimmune pathology by
instillation of autoantigen-reactive Tregs in models of diabetes
(13) and gastritis (14) and in experimental autoimmune enceph-
alomyelitis (EAE) (15). However, concerns have been raised re-
cently over the potential of Treg-based therapy because of
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convincing demonstrations that IL-6 (16) and other proinflam-
matory cytokines associated with the Th17 developmental path-
way (IL-23, IL-1b, and TGF-b) can provoke nTregs to lose Foxp3
expression and produce IL-17 (16–18). This transition requires
STAT3, RORgT, and RORa activity (18). Cells coexpressing
Foxp3 and RORgT have been identified in humans (19), and
stimulation of human Foxp3+ cells in the presence of IL-1b,
IL-23, and IL-21 has also been shown to promote their production
of IL-17 (20, 21). In light of these results, it is important to
question whether Foxp3+ cells can develop pathogenic activity. A
recent study has reported that “ex-Foxp3+” cells were capable of
effector cytokine production and displayed pathogenic potential
upon transfer to naive lymphopenic mice (22). An extrapolation
from that study is that in vitro-generated human iTregs may have
similar plasticity in function. Moreover, activated autoantigen-
reactive Tregs are the most effective agents for Treg-based ther-
apy in the mouse (13–15, 23). A recent study by Zhang et al. (24)
provided a precise dissection of the role of antigenic reactivity in
the suppression of EAE and presented two important observations:
Ag-reactive iTregs can expand in vivo upon encounter with their
cognate Ag, and iTreg-mediated suppression in vivo is Ag-specific
in nature. These findings strengthen the case for the therapeutic
use of Ag-reactive iTregs and the attendant need to investigate
the phenotypic stability of these cells. The production of IL-6 at
sites of autoimmune inflammation has been reported to influence
negatively the suppressive capacity of Tregs (25). Furthermore it
is known that IL-6, IL-12, IL-23, and TGF-b are expressed in the
inflamed CNS during EAE (26–28) and that these cytokines
profoundly influence the function of effector T cells (28, 29). Thus
it is possible that Tregs at inflammatory sites are exposed to
cytokines that are not only capable of overcoming their suppres-
sive function but may also favor their transition toward a proin-
flammatory phenotype. Therapeutic use of autoantigen-reactive
human iTregs could have profound consequences if this potential
for conversion to effector function were to be realized in a patient.
This risk provides an imperative to understand the functional
plasticity of iTregs in vitro and how this might translate into un-
desirable activity in autoimmune disease in vivo.
In this study, we compared nTregs and iTregs in their responses
to stimulation in the presence of proinflammatory cytokines. iTregs
proved to be resistant to the induction of IL-17 production in vitro
but readily deviated from Foxp3 expression toward a Th1-like
phenotype, particularly in the presence of IL-12. We tested the
consequence of this in the setting of EAE and found that reac-
tivation in the presence of IL-12 provided Foxp3+ iTregs with the
capacity to home to the CNS and to initiate low-grade clinical
pathology. However, these “IL-12–conditioned iTregs” also retained
some suppressive capacity, the ability to suppress the proliferation
of naive T cells. Collectively, these data show that although iTregs
can gain effector function, their pathogenic potential in vivo is
limited compared with that of primary Th1 effectors of the same
specificity.
Materials and Methods
Mice, Ags, and tissue culture medium
C57BL/6 (either CD45.2 or CD45.1), Foxp3-GFP reporter mice (30), Tg4
mice (31) (either CD45.2, CD45.1, or CD90.1), B10.PL3C56BL/6 mice,
and IFN-g2/2 mice were used. Foxp3.LuciDTR-4 mice (32) were crossed
with CD45.1 Tg4 mice to obtain CD45.1+ Tg43Foxp3.LuciDTR-4 mice.
All mice were bred under specific pathogen-free conditions at the Uni-
versity of Edinburgh (Edinburgh, U.K.). All experiments had local ethical
approval and were performed in accordance with U.K. legislation. The
myelin basic protein (MBP) Ac1-9 and MOG35–55 (pMOG) peptides were
obtained from Cambridge Research Biochemicals (Cleveland, U.K.). Tis-
sue culture medium (RPMI 1640 medium) was supplemented with 2 mM
L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 5 3 1025
M 2-mercaptoethanol (all from Invitrogen Life Technologies, Paisley,
U.K.) and 10% FCS (Sigma, Poole, U.K.).
Active induction of EAE
B10.PL3C57BL6 mice received 1 3 106 Tg4 CD4+ T cells with or
without 1 3 106 Tg4 iTregs treated as indicated in the text. One day later,
mice received 100 mg Ac1-9 peptide emulsified in CFA containing 50 mg
heat-killed Mycobacterium tuberculosis H37Ra (Sigma-Aldrich, Poole,
U.K.) at a final volume of 100 ml injected s.c. into the hind legs. On the
day of immunization and 48 h later, each mouse also received 200 ng
pertussis toxin (Health Protection Agency, Dorset, U.K.) in 0.5 ml PBS i.p.
C57BL/6 mice were immunized as above, using 100 mg pMOG per mouse.
Clinical signs of EAE were assessed daily with the following scoring
system: 0, no signs; 1, flaccid tail; 2, impaired righting reflex and/or gait; 3,
partial hind limb paralysis; 4, total hind limb paralysis; 5, hind limb pa-
ralysis with partial front limb paralysis; and 6, moribund or dead.
Cell culture and passive induction of EAE
For Th1 polarization, Tg4 splenocytes were cultured at 4 3 106 cells ml
with 10 mg/ml MBP(Ac1-9), 25 ng/ml rIL-12, 0.5 ng/ml rIL-2 (both from
R&D Systems, Minneapolis, MN), and 25 ng/ml rIL-18 (MBL, Nagoya,
Japan) as described previously (33). Cells were harvested after 72-h culture
and 3 3 106 blasts transferred i.v. Some mice also received IL-12–con-
ditioned iTregs as indicated in the text. On the day of cell transfer, each
mouse also received 200 ng pertussis toxin (Health Protection Agency,
Dorset, U.K.) in 0.5 ml PBS i.p. Clinical signs of EAE were assessed as
described earlier.
iTreg generation
CD4+ T cells were purified using magnetic cell sorting (Miltenyi Biotec,
Bergisch Gladbach, Germany) prior to surface staining and sorting by
FACS. GFP2 CD4+ T cells were cultured for 5 d on anti-CD3 (clone
145.2C11; eBioscience, Hatfield, U.K.) plus anti-CD28 (clone 37.51;
e-Bioscience) coated plates in the presence of 5 ng/ml TGF-b (R&D
Systems) and 100 U/ml IL-2 at a density of 0.25 3 106 to 0.5 3 106/well
in 24-well plates. After 5 d of culture, GFP-expressing cells were purified
by FACS sorting. In some experiments, GFP+ iTregs received secondary
stimulation with anti-CD3 in the presence of IL-12 (25 ng/ml), IL-6 (30
ng/ml), IL-23 (30 ng/ml), IL-1b (10 ng/ml), TGF-b (2.5 ng/ml) (all R&D
Systems) individually or in combination as described in the text. In some
cases (as indicated), cultures were supplemented with anti–IFN-g (clone
XMG1.2; Bio X Cell, West Lebanon, NH) at 10 mg/ml. The level of cy-
tokine production during culture was assessed by ELISA.
Preparation of CNS-infiltrating mononuclear cells
Mice were sacrificed by CO2 asphyxiation, perfused with cold PBS, and
mononuclear cells were prepared from brain and spinal cord as described
previously (34).
Abs and FACS analysis
Cells were stained using the following Abs and isotype controls (all from
eBioscience, except where stated): anti-CD4–allophycocyanin, anti-CD4–
PE, anti-CD4–PerCP, anti-CD4–AF700 (BD Pharmingen, Oxford, U.K.)
anti-CD45.1–(FITC/PE/PerCPCy5.5/allophycocyanin), anti-CD25–(FITC/
PE) (clone 7D4; Miltenyi Biotec, Bergisch Gladbach, Germany), anti-
CD25–(PE/allophycocyanin) (clone PC61; BD Pharmingen), anti-CD90.1–
(PE/allophycocyanin), anti-CD62L–FITC, anti–IFN-g–FITC, anti–IL-17–
PE, anti–IL-17–allophycocyanin (Biolegend, San Diego, CA), anti-GITR–
allophycocyanin, anti-CTLA4–PE, anti–T-bet–PerCPCy5.5 (clone
ebio410), anti–Mac-1–efluor 450, anti-Foxp3–efluor 450, rat IgG1–(FITC/
PE/allophycocyanin/PerCPCy5.5), and rat IgG2b–PE. FACS data were
collected on FACSCalibur, FACSCanto, LSR-II, or Fortessa flow cytometers
(BD Biosciences, Franklin Lakes, NJ). FACS sorting was performed using
Aria/Aria II cell sorters (BD Biosciences), and all data were analyzed using
FlowJo software (Tree Star, Ashland, OR).
For intracellular staining in response to peptide, cells were resuspended at
1 3 107/ml in the presence or absence of 20 mg/ml Ac1-9 or pMOG. After
overnight culture, 1ml/ml brefeldinA (eBioscience; 10003 stock) was added
for the last 4 h of culture. For staining at the end of polarizing culture, 50 ng/ml
PMA, 50 ng/ml ionomycin, and 1ml/ml brefeldin Awas added for the last 4 h
of culture. Cells were washed once in FACS buffer (PBS, 2% FCS, 0.01%
NaN3) and surface stained prior to processing for Foxp3 staining using pro-
prietary buffers according to the manufacturer’s instructions (eBioscience).
After overnight incubation in Foxp3 fix/perm buffers, cells were stained for
intracellular Ags. Due to loss of GFP activity as a result of fixation, cells
from Foxp3.LuciDTR-4 mice were stained with anti-Foxp3.
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In vitro proliferation and suppression assays
Freshly isolated CD4+CD25– cells or various Treg populations were cul-
tured at 2 3 104 per well for 96 h with 1 3 105 irradiated (30 Gy) splenic
APCs and 1 mg/ml anti-CD3 (clone 145.2C11; eBioscience). [3H]Thy-
midine deoxyribose (0.5 mCi; Amersham Biosciences, Amersham, U.K.)
was added for the final 18 h of culture, and incorporation was measured
using a liquid scintillation b-counter (Wallac, Turku, Finland). Mean cpm
of triplicate cultures are shown in Fig. 5A.
For suppression assays, 2 3 105 CFSE-labeled CD45.1+CD4+
responder cells were cocultured at a 1:1 ratio with CD45.2 IL-12–condi-
tioned iTregs or with control iTregs that had received an identical sec-
ondary stimulation but without inclusion of IL-12, 1 mg/ml anti-CD3, and
irradiated APCs. Cultures were plated in triplicate in 48-well plates, and
CFSE dilution in the CD45.1+ responder cells was measured after 72-h
culture.
Statistical analysis
Statistical analysis of results was performed using the Mann–Whitney U
test, the two-tailed Student t test, and one-way ANOVAwith Bonferroni’s
multiple comparison test.
Results
nTregs produce IL-17, whereas iTregs produce IFN-g upon
secondary stimulation
There are conflicting reports concerning the capacity of iTregs to
produce IL-17 (16–18). To provide populations of Ag-reactive
Tregs, Tg4 mice (31) that express a transgenic TCR recognizing
the Ac1-9 peptide of MBP in association with Au were crossed
with Foxp3.LuciDTR-4 mice (BAC transgenics expressing eGFP
under the Foxp3 promoter) (32), thereby producing Tg43Foxp3.
LuciDTR-4 mice. To compare directly the ability of nTregs and
iTregs to produce IL-17, we generated highly purified populations
of Foxp3+ iTregs and freshly isolated nTregs and stimulated them
in the presence of a cytokine mixture reported to give optimal
induction of IL-17 in nTregs (18) (see schematic Fig. 1A). As
anticipated, these conditions provoked approximately one in three
nTregs (sorted CD4+CD62LhiGFP+ cells from Tg43Foxp3.
LuciDTR-4 mice) to produce IL-17. Of these IL-17 producers,
around two thirds retained Foxp3 expression (Fig. 1B, left panels).
To our surprise, although exposure to Th17-inducing conditions
led to loss of Foxp3 expression in around 75% of iTregs, this did
not allow them to produce IL-17. Instead, there was a clear pop-
ulation producing IFN-g, of which approximately two thirds were
Foxp32 (Fig. 1B, right panels). Thus, there was a striking dif-
ference in how nTregs and iTregs responded to pro-Th17 con-
ditions; nTregs produced IL-17, but not IFN-g, whereas iTregs
produced IFN-g, but not IL-17.
The frequency of GFP+ cells after the initial iTreg sort was
routinely .97% and in some experiments .99% (see Supple-
mental Fig. 1). Furthermore, “spiking” experiments, in which
known frequencies of traceable GFP2 cells (sorted from parallel
cultures under iTreg conditions) were added to sorted GFP+ cells,
confirmed that the ultimate GFP2 population was derived chiefly
from conversion of GFP+ cells, rather than an outgrowth contami-
nating GFP2 cells remaining postsort (Supplemental Fig. 1).
Having uncovered the ability of iTregs to produce IFN-g under
Th17 conditions, we next tested whether this ability could be
magnified under alternative in vitro cytokine conditions. iTregs
(sorted for Foxp3 expression after the initial iTreg culture) pro-
duced IFN-g upon secondary TCR stimulation, even in the ab-
sence of exogenous cytokines. The cytokines composing the Th17
mixture did not markedly increase the proportion of IFN-g–
producing cells when used singly or in combination (Fig. 1C).
However, IL-12 induced a pronounced increase in the frequency
of IFN-g–producing cells (Fig. 1C). IL-17 production among
iTregs was not seen in any of the conditions tested (data not
shown). The majority of cells lost expression of Foxp3 under all
conditions tested, even when stimulated in the presence of TGF-b
alone (data not shown). Given that it is present in many tissues
undergoing autoimmune inflammation, the ability of IL-12 to
trigger production of IFN-g in iTregs is highly pertinent to their
role in modulating inflammation in vivo.
Endogenous production of IFN-g during in vitro induction of
iTregs
The ability to produce IFN-g in response to IL-12 is governed by
signals from both the TCR and the IFN-g receptor, which initiate/
stabilize T-bet expression. Our iTreg conditions provided a TCR
stimulus (anti-CD3) but no additional IFN-g. To test whether there
was endogenous IFN-g in iTreg cultures, we sorted Foxp3(GFP)2
cells from naive mice, exposed them to iTreg conditions, and
performed kinetic analyses for the expression of Foxp3, IFN-g,
and T-bet (Figs. 2, 3). A significant Foxp3+ fraction could be seen
FIGURE 1. nTregs and iTregs respond differently to stimulation in the
presence of proinflammatory cytokines. A, Schematic outlining the prep-
aration of Foxp3+ nTreg and iTreg populations. B, Expression of Foxp3,
IL-17, and IFN-g by nTregs (left) and iTregs (right) after stimulation with
plate bound anti-CD3/anti-CD28 in the presence of IL-6, IL-23, and TGF-
b. C, The percentage of iTregs producing IFN-g after 72-h stimulation in
the presence of the indicated cytokines. The proportion of cells producing
IFN-g in the presence of IL-6, IL-23, and TGF-b varied between experi-
ments from 5.5 to 25% giving a mean of 15.4 6 6.6%. Data are from one
of three experiments giving consistent results.
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after 48 h, and this leveled at around 75% from 72 h onwards (Fig.
2A). Detectable IFN-g appeared in iTreg supernatants from 72 h
(Fig. 2B). Intracellular staining for Foxp3 and IFN-g revealed
that by 48 h, IFN-g–producing cells were apparent under iTreg
conditions, and, of these, about half were Foxp3+ (Fig. 2C). No-
tably, when cells were stimulated under neutral conditions, IFN-g
was produced by Foxp32 cells only (Fig. 2C). Thus, there was
a clear source of IFN-g in the iTreg cultures and at least some of
this was produced by cells that had already initiated Foxp3 ex-
pression.
T-bet expression in Foxp32 and Foxp3+ cells during the
generation of iTregs
Expression of the Th1-associated transcription factor T-bet has
been identified in a minor population of nTregs (35), and epigenetic
modifications of Tbx21 have identified it as a gene poised for
expression in nTregs (36). Having found Foxp3+ iTregs to be re-
sponsive to IL-12 and capable of IFN-g production, we questioned
whether iTregs also expressed T-bet. We sorted Foxp32(GFP2)
CD4+ T cells from naive mice and monitored T-bet expression
over time during stimulation under iTreg-inducing conditions.
Prior to stimulation, there was no evidence of T-bet expression in
the starting population (Fig. 3, top left panel). Expression of T-bet
was increased after 24 h in the absence of TGF-b (Fig. 3, left
panels) and more markedly by 48 h. There was also an increase in
T-bet expression under iTreg conditions that, although less marked
at 24 h, was clearly upregulated by 48 h and maintained at 72
h (Fig. 3). It was notable that the increase in T-bet expression
occurred to a similar extent in both Foxp32 and Foxp3+ cells.
iTreg expression of T-bet is IFN-g dependent
Having identified an endogenous source of IFN-g in iTreg cul-
tures, we tested whether this was required for T-bet expression by
iTregs and/or their subsequent ability to produce IFN-g upon
restimulation. During iTreg generation, cells from IFN-g2/2 mice
did not express T-bet (Fig. 4A). Moreover, whereas wild-type
iTregs showed a marked ability to upregulate T-bet upon sec-
ondary stimulation in the presence of IL-12 (i.e., IL-12–condi-
tioned iTregs), this was disabled in IFN-g2/2 iTregs (Fig. 4B).
Ab-mediated neutralization of IFN-g during initial iTreg cultures
led to reduced T-bet expression in wild-type cells (Fig. 4C). No-
tably, anti–IFN-g also increased the frequency of Foxp3+ cells
achieved in the initial iTreg cultures (Fig. 4D), an enhancement
also seen when using IFN-g2/2 cells (data not shown), and in-
creased production of IL-17 (Fig. 4E). Finally, when CD252CD4+
T cells from CD45.2 IFN-g2/2 mice were cultured together with
CD45.1 IFN-g–sufficient cells under iTreg conditions, both pop-
ulations were able to express T-bet (Fig. 4F). We therefore can
conclude that exposure to IFN-g during iTreg culture is a pre-
requisite for T-bet expression and subsequent sensitivity to IL-12–
mediated conversion to an IFN-g–producing phenotype.
IL-12–conditioned iTregs lose their anergic phenotype but still
suppress naive T cell expansion in vitro and in vivo
A large proportion of Foxp3+ iTregs lose expression of Foxp3 on
secondary stimulation in vitro (Fig. 1B). The continued expression
of functional Foxp3 is necessary to maintain suppressive function
and to prevent adoption of effector cytokine production in nTregs
(11). With this in mind, we sorted Foxp3+ cells from primary
iTreg cultures, exposed them to secondary TCR stimulation in the
presence of IL-12 (IL-12–conditioned iTregs), and assessed their
suppressive capacity. IL-12–conditioned iTregs differed from
nTregs or iTregs in that they lost their anergic phenotype when
given a tertiary stimulation with anti-CD3 (Fig. 5A). However,
they behaved similarly to iTregs that had been maintained in
FIGURE 2. IFN-g production is induced in Foxp32 and Foxp3+ cells
during the generation of iTregs. Sorted CD4+GFP2 cells were cultured
with anti-CD3/anti-CD28 under iTreg conditions or without addition of
TGF-b (No TGF-b added). A, Expression of Foxp3 over time. B, Pro-
duction of IFN-g over time as determined by ELISA. C, Intracellular
staining for Foxp3 and production of IFN-g in cells sampled after 48 h of
culture. Data are from one of two experiments giving consistent results.
FIGURE 3. T-bet expression is induced in Foxp32 and Foxp3+ cells
during the generation of iTregs. Cultures were established as described for
Fig. 2. Expression of T-bet (open histogram) over isotype control (gray
histogram) prior to in vitro stimulation (top left panel) and over time in
non-iTreg conditions (left panels) or under iTreg conditions gating on
Foxp32 cells (middle panels) and Foxp3+ cells (right panels). Data are
representative of two experiments giving consistent results.
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medium without IL-12 in their ability to inhibit the proliferation of
naive CFSE-loaded T cells upon in vitro coculture (Fig. 5B). IL-
12–conditioned iTregs maintained expression of CTLA4 and
GITR, although at lower levels than those of iTregs (data not
shown).
We next assessed the capacity of IL-12–conditioned iTregs to
limit the Ag-driven expansion of CD4+ T cells in vivo. First, we
established that primary iTregs showed suppressive activity
in vivo. We transferred traceable (CD90.1+) MBP-reactive Tg4
T cells (representing our “responder” population) into B10.
PL3C57BL/6 hosts, either alone or in the presence of primary
Tg4 iTregs (generated from Tg43Foxp3.LuciDTR-4 mice) prior
to immunization with the MBP Ac1-9 peptide in CFA. This is an
informative model system because the host mice only develop
EAE in response to immunization with the Ac1-9 peptide if they
have first received a cohort of naive Tg4 T cells (37). This means
that the Tg4 cells are necessary for the initiation of the CNS in-
flammation and that analysis of their fate is highly pertinent to
disease outcome. The co-transfer of iTregs reduced the clinical
severity of disease, and this correlated with the presence of fewer
MBP-reactive CD90.1+ responder cells in both the spleen and the
CNS (Supplemental Fig. 2). These data are consistent with the
reported ability of iTregs to limit the clonal expansion of naive
T cells in other experimental models of pathology (14, 38).
Using the same model system, we found that co-transfer of
CD45.1+ IL-12–conditioned iTregs with CD90.1+ “responder”
Tg4 T cells significantly inhibited both the increase in cellularity
of the draining lymph nodes (Fig. 5C) and the expansion of the
responder Tg4 cells seen upon immunization (Fig. 5D). Only very
low numbers of IL-12–conditioned iTregs could be recovered
FIGURE 4. IFN-g induces T-bet expression and responsiveness to IL-12
in iTregs. A, Expression of T-bet (open histogram) over isotype control
(gray histogram) among Foxp32 and Foxp3+ cells from wild-type (left)
and IFN-g2/2 (right) mice cultured under initial iTreg conditions (sampled
after 5 d). B, iTregs from wild-type and IFN-g2/2 mice then received
secondary stimulation with anti-CD3 in the presence or absence of IL-12.
Expression of T-bet in wild-type (upper panels) and IFN-g2/2 (lower
panels) iTregs 72 h after secondary stimulation is shown. The level of
background staining using appropriate isotype controls for T-bet and
Foxp3 is shown in the left-hand panel. C–E, iTregs were generated from
wild-type mice by initial culture under iTreg conditions in the presence
or absence of anti–IFN-g (clone XMG1.2). Frequency of cells expressing
T-bet (C) and Foxp3 (D) and the presence of IL-17 in culture supernatants
(E) was assessed after 72 h. F, iTregs were generated by initial culture
under iTreg conditions of CD252CD4+ T cells from wild-type (CD45.1)
and IFN-g2/2 (CD45.2) mice either alone (upper panels) or in coculture at
a 1:1 ratio (bottom panel). T-bet expression was assessed after 72 h. Data
are from one of three experiments giving consistent results.
FIGURE 5. IL-12–conditioned iTregs suppress the proliferation of
naive responder cells in vitro and in vivo. A, Proliferation of freshly
isolated Foxp32 cells, freshly isolated nTregs, iTregs, and IL-12–condi-
tioned iTregs (IL-12-iTreg) in response to anti-CD3. B, GFP+ iTregs re-
ceived secondary stimulation for 72 h with anti-CD3 in the absence
(iTreg) or presence (IL-12-iTreg) of IL-12. These cells were then cultured
for 72 h at a 1:1 ratio with freshly isolated, CFSE-labeled CD45.1+CD4+
CD252 responder cells and irradiated APCs, with or without anti-CD3.
C–E, Naive CD90.1+CD45.12 Tg4 T cells (1 3 106) were transferred to
B10.PL3C57BL/6 hosts either alone or together with 1 3 106 CD90.12
CD45.1+ Tg4 IL-12–conditioned iTregs 1 d prior to immunization with
Ac1-9 for the induction of EAE. C, Cellularity of the draining lymph
nodes 6 d postimmunization. D, Number of CD90.1+Tg4 T cells (solid
bars) and CD45.1+Tg4 IL-12–conditioned iTregs (open bar) recovered
from the draining lymph nodes 6 d after immunization. E, Clinical course
of EAE (n = 4 per group). Data are from one of two experiments giving
consistent results. *p # 0.05 as determined by ANOVA.
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from the draining lymph node (Fig. 5D) suggesting competition
for Ag does not account for the observed suppression. The ability
to limit the expansion of MBP-reactive responder cells was
reflected in the reduced incidence and severity of EAE seen in
recipients of IL-12–conditioned iTregs (Fig. 5E). Thus, despite
only 2% of their number being Foxp3+ at the time of transfer (data
not shown), IL-12–conditioned iTregs can suppress the in vivo
expansion of autoreactive T cells and thereby limit the develop-
ment of pathology.
IL-12–conditioned iTregs display limited pathogenic potential
and do not prevent passive transfer of EAE
Having observed IL-12–conditioned iTreg expression of T-bet and
capacity for IFN-g production, we sought to determine whether
IL-12–conditioned iTregs displayed any pathogenic potential
themselves. We used a well-characterized model of passive EAE
induction whereby disease is initiated by the transfer of activated
Tg4 T cells (33). This allowed us to assess both the pathogenic
potential of our MBP-reactive Tg4 IL-12–conditioned iTregs and
their ability to influence the pathogenicity of preformed effector
T cells.
Th1 polarized Tg4 cells readily induced disease when transferred
in numbers as low as 1 million (Fig. 6A). In contrast, transfer of
3 million IL-12–conditioned iTregs did not result in any overt
pathology (Fig. 6A). Transfer of more than 4 million Th1 polar-
ized cells leads to a high mortality rate in this model, precluding
titration to higher numbers of Th1 cells. When we transferred
higher numbers of IL-12–conditioned iTregs (6 million), recipient
mice developed clinical signs of EAE, but disease was slower in
onset, milder in severity, and shorter in duration than that seen
with lower numbers of bona fide Tg4 effectors (Fig. 6B). IL-12–
conditioned iTregs were enriched within the CNS, lacked Foxp3
expression (Fig. 6C), and could produce IFN-g in response to
peptide restimulation ex vivo (Fig. 6D). Thus, despite having
a similar capacity for IFN-g production as primary Th1 cells at the
time of their infusion (Supplemental Fig. 3), IL-12–conditioned
iTregs have limited pathogenic potential in this model. This could
not be accounted for by a protective effect of iTreg-derived IL-10
because we could not detect any IL-10 production by these cells as
measured by ELISA (data not shown).
To determine whether IL-12–conditioned iTregs influenced the
development of pathology initiated by Th1 effector cells, host
mice were given Tg4 Th1 effectors either alone or together with
an equal number of either IL-12–conditioned Tg4 iTregs or Tg4
iTregs that had not been conditioned further with IL-12. No sig-
nificant differences between these groups were seen in incidence
or severity of disease (Fig. 6E). The relative lack of pathogenic
potential in IL-12–conditioned iTregs is further illustrated by the
fact they did not exacerbate disease in co-transferred mice.
Tg4 Th1 cells that received secondary in vitro stimulation in the
presence of IL-12 maintained their encephalitogenic function
in vivo (Supplemental Fig. 4). This confirmed that the limited
pathology seen with IL-12–conditioned iTregs was not simply
a function of their exhaustion imposed by repeated triggering of
their TCR in vitro. Notably, co-transfer of Th1 cells significantly
increased the frequency of IL-12–conditioned iTregs recovered
from the CNS suggesting that they are actively recruited to sites of
Th1 inflammation (Supplemental Fig. 5).
Discussion
We describe, to our knowledge, a novel functional division be-
tween nTregs and iTregs in their responses to proinflammatory
cytokines. nTregs display a greater propensity for IL-17 pro-
duction than that of iTregs, which are more predisposed to IFN-g
production in vitro. IFN-g released during the in vitro generation
of iTregs induces their coexpression of T-bet and Foxp3 and
enhances their sensitivity to IL-12. IL-12 in turn heightens T-bet
expression and induces high levels of IFN-g production in pre-
viously Foxp3+ cells. The gain of Th1-like effector function is
accompanied by effector-like homing properties and sufficient
proinflammatory activity to produce mild clinical CNS pathology.
This previously unappreciated role for IFN-g in conditioning the
responsiveness of iTregs to cytokine stimulation highlights po-
tential dangers in the therapeutic application of autoreactive
iTregs.
The potential for Foxp3+ nTregs to gain a capacity for IL-17
production after stimulation in the presence of inflammatory
FIGURE 6. IL-12–conditioned iTregs display modest pathogenic po-
tential and are recruited to the site of type 1 inflammation. A, Clinical
course of EAE in mice receiving graded numbers of Th1 polarized Tg4
cells (as indicated [open symbols]) or IL-12–conditioned Tg4 iTregs (3 3
106 per mouse [solid symbols]). B, Clinical course of EAE in mice given
6 3 106 IL-12–conditioned Tg4 iTregs. C, Foxp3 (GFP) status of CD45.1+
IL-12–conditioned Tg4 iTregs recovered from the CNS. D, Production of
IFN-g and IL-17 by IL-12–conditioned iTregs (gated on CD45.1+ cells)
recovered from the CNS in response to overnight stimulation in the
presence (right) or absence (left) of Ac1-9. E, Clinical course of EAE in
mice receiving Tg4 Th1 effectors alone (solid symbols) or in co-transfer
with primary Tg4-iTreg (open squares) or IL-12–conditioned Tg4 iTregs
(open circles), each at 3 3 106 per mouse. n = 4 to 6 mice per group. Data
are from one of two experiments giving consistent results.
7240 EFFECTOR PROPERTIES OF EX-iTreg
 by guest on M
arch 1, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
cytokines (principally IL-6, IL-23, and IL-1b) has been identified
in murine (16–18) and human (20, 21) T cells. Although most
studies of this transition have been carried out in vitro, cells with
the potential to coexpress Foxp3 and IL-17 have been identified in
mice in the lamina propria (39) and in human peripheral blood
(19). The capacity of Foxp3+ cells (key players in peripheral
tolerance) to produce IL-17 presents an uncomfortable dichotomy
in terms of functional classification. However, demonstrable ef-
fects of this change in terms of pathology have remained elusive.
The most successful experimental applications of Treg-based
therapies have used Ag-reactive Tregs (13–15, 23, 24), and the
most expedient means of obtaining such cells, in significant
numbers, is via the TGF-b–mediated induction of Foxp3 expres-
sion in vitro (40). iTregs have shown their therapeutic potential in
models of organ-specific autoimmune disease (14, 24, 41) and in
preventing the development of pathology in scurfy mice (42).
However, there is conflicting literature regarding the capacity of
iTregs for IL-17 production. An initial report declared iTregs re-
sistant to conversion (17), but a subsequent paper provided evi-
dence that both nTregs and iTregs could be converted to “Th17”
cells (18). We show here that iTregs are indeed resistant to con-
version toward IL-17 production, with the previously unappre-
ciated role of IFN-g accounting for the above contradiction. Yang
et al. (18) (unusually) included a neutralizing Ab to IFN-g in their
primary iTreg conditions, whereas Zheng et al. (17) used only
TGF-b and IL-2. Without exposure to IFN-g, iTregs fail to express
T-bet during their in vitro generation and subsequently are able to
produce IL-17 under pro-Th17 cytokine conditions, whereas ini-
tial exposure to IFN-g promotes resistance to this transition. This
unexpected conditioning of iTregs illustrates how differential re-
sponsiveness can be engendered in iTregs during their generation
and offers a means of subtly programming responsiveness to fu-
ture stimuli.
The pathogenic potential of Tregs is a key question, given that
their continued expression of Foxp3 seems necessary to maintain
full suppressive function (11, 43). Reduced or ablated Foxp3 ex-
pression can lead to Treg function shifting toward a Th2 or a Th1
profile, respectively (11, 43), rather than Th17. When Tregs with
a deletion of Foxp3 were transferred to lymphopenic hosts, they
proliferated and were found among tissue-infiltrating cells sug-
gesting an involvement in pathology (11). Serial transfer experi-
ments have shown that Foxp3+ cells transferred to lymphopenic
hosts lose Foxp3 expression and on secondary transfer (again into
lymphopenic hosts) promote tissue infiltration and damage (44).
The question of whether pathology seen in the absence of
“normal” Treg function is due to unhindered responsiveness of
T cells that have never expressed Foxp3 or to the “would be” or
“had been” Tregs themselves is not simple. An elegant inves-
tigation into this division used scurfy mice crossed with DEREG
mice (which express GFP under the control of an additional Foxp3
promoter). These mice allowed the effector function and patho-
genic potential of those cells that would normally have been
Foxp3+, but lacked functional Foxp3, to be assessed. Transfer of
these “would be” Tregs to RAG12/2 mice did not transfer the
scurfy phenotype, whereas transfer of conventional GFP2 T cells
did, indicating the pathogenic potential lies in the effector cells,
not the defective Treg compartment (45). The strongest evidence
that cells that have previously expressed Foxp3 can go on to gain
some pathogenic activity comes from experiments using mice in
which cells that have expressed Foxp3 at any time express YFP,
and those cells currently expressing Foxp3 express GFP. Thus,
previously Foxp3+ and currently Foxp32 cells display a YFP+
GFP2 phenotype. When such ex-Foxp3+ cells with specificity for
a pancreatic islet autoantigen were expanded in vitro and trans-
ferred to NOD Rag22/2 mice, the recipients developed rapid and
severe diabetes (22).
It is surely important to note that all of the above examples
suggesting pathogenic activity among Treg populations have used
transfer into lymphopenic hosts. Extrapolation from pathology
observed in such unfettered lymphopenic environments to what
might occur upon transfer to hosts with normal immune com-
plements is difficult. To our knowledge, our study is the first to
report pathogenic activity after transfer of former Foxp3+ cells
into lympho-replete hosts.
To date, there is no direct evidence for IL-17 production by Tregs
having a detrimental function in vivo. Our approach assessed the
function of iTregs of known provenance; iTregs that previously
expressed Foxp3 gave rise to a population of cells expressing T-bet
and IFN-g, and these cells were able to provoke CNS in-
flammation. We found no evidence of IL-17 production by IL-12–
conditioned iTregs prior to transfer or upon recovery from the
CNS; however, this does not exclude the possibility that these cells
may have produced IL-17 at some point posttransfer. Although
endowed with Th1-like characteristics, our IL-12–conditioned
iTregs were (on a per cell basis) less pathogenic than Th1 cells of
the same specificity. The transfer of 6 million Th1 cells results in
fatal disease (data not shown), whereas this number of IL-12–
conditioned iTregs produced only mild pathology. However,
though less pathogenic than bona fide effector cells, this remains,
to our knowledge, the first evidence of previously Foxp3+ cells
inducing inflammation in an immunologically intact host.
Conditions favoring T-bet expression and IFN-g production by
Tregs can be generated by infection in vivo, and coexpression of
Foxp3 and T-bet has also been associated with negative con-
sequences during lethal infection with Toxoplasma gondii (46).
However, there is a profound decrease in Treg numbers during
this infection. In the face of an overwhelming Th1 response, it is
therefore impossible to say whether IFN-g production by the low
numbers of remaining Tregs definitively contributes at all to pa-
thology in that model (46). We found that MBP-reactive, pre-
viously Foxp3+ cells (IL-12–conditioned iTregs) were capable of
promoting inflammatory pathology in vivo in the absence of any
additional “help” from T effectors. Given that IL-12–conditioned
Tregs also retained suppressive activity (upon naive T cells in
vivo) and had comparatively low virulence on transfer, we con-
clude that despite T-bet expression and IFN-g production, they are
not equivalent to primary Th1 effectors. It is notable that when
co-transferred with pathogenic Th1 cells, IL-12–conditioned
iTregs were recovered from the inflamed CNS in greater numbers
than when they were transferred alone. In this setting, they neither
attenuated nor exacerbated disease severity. Thus, unlike freshly
isolated nTregs, iTregs have a capacity to target the CNS (41, 47),
and we have shown that IL-12–conditioned iTregs retain this
ability. The fact that CNS recruitment of IL-12–conditioned iTregs
was enhanced by the co-transfer of pathogenic Th1 cells suggests
that iTregs can show an inflammation-seeking phenotype, a de-
sirable characteristic in cells aimed for therapeutic application.
Tbx21 expression shows a broad spectrum of epigenetic states
suggesting complex regulation, and epigenetic modifications as-
sociated with gene activation and gene repression colocalize in
the promoter region of Tbx21 in Tregs (36). Such colocalization is
thought to mark genes that are “poised” for expression, and nTregs
can be induced to express T-bet and produce IFN-g upon stimu-
lation in the presence of IL-12. This state of readiness to ex-
press T-bet may be required to allow regulatory responses to be
tuned appropriately to effector responses, and it is interesting to
note that similar modifications were found in both Rorc and Gata3
(36). Whether exposure to proinflammatory cytokines during an
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immune response influences the stability of Tregs via epigenetic
modification is an important area of future study.
Increasingly, promiscuity in the expression of “subset specific”
transcription factors in T cells is becoming appreciated (48). In this
study, exposure to IFN-g endowed iTregs with certain Th1-like
characteristics (expression of T-bet and elevated responsiveness
to IL-12). The idea that Tregs can “co-opt” elements of effector
phenotype, perhaps via the empathetic expression of chemokine
receptors, seems an efficient way to tune regulatory responses to the
effector responses they aim to control. Of direct relevance to our
study, coexpression of T-bet in a subset of Foxp3+ cells is reported
to promote efficient control of type 1 inflammation through their
expression of CXCR3 (35). Thus, coexpression of Foxp3 and ef-
fector-associated transcription factors (perhaps in response to low
levels of effector cytokines) can be beneficial in terms of regula-
tion. As techniques allowing the expression history of genes of
interest to be visualized become available, our understanding of the
dynamics of coexpression should progress rapidly.
In conclusion, we provide, to our knowledge, the first evidence
of previously Foxp3+ cells eliciting inflammatory pathology in im-
munologically intact hosts. At face value, this strikes a cautionary
note for the therapeutic development of iTregs. However, despite
production of IFN-g, previously Foxp3+ cells were only weakly
pathogenic compared with primary Th1 cells, they retained some
suppressive function, and they showed an inflammation-seeking
phenotype. Although our current markers of “regulatory” and
“effector” cells are clearly showing their limitations, further clar-
ity on the mechanistic basis for T cell subset plasticity will allow
better prediction of in vivo outcome and new means to control the
stability of Treg function therapeutically.
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